Fluvoxamine Exerts Sigma-1R to Rescue Autophagy via Pom121-Mediated Nucleocytoplasmic Transport of TFEB

Chun-Yu Lin,Hsiang-En Wu,Eddie Feng-Ju Weng,Hsuan-Cheng Wu,Tsung-Ping Su,Shao-Ming Wang

DOI: https://doi.org/10.1007/s12035-023-03885-9

IF: 5.682

2024-01-07

Molecular Neurobiology

Abstract:Expansion of the GGGGCC-RNA repeat is a known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which currently have no cure. Recent studies have indicated the activation of Sigma-1 receptor plays an important role in providing neuroprotection, especially in ALS and Alzheimer's disease. Nevertheless, the mechanisms underlying Sigma-1R activation and its effect on (G 4 C 2 )n-RNA-induced cell death remain unclear. In this study, we demonstrated that fluvoxamine is a Sigma-1R agonist that can increase chaperone activity and stabilize the protein expression of Pom121 in (G 4 C 2 ) 31 -RNA-expressing NSC34 cells, leading to increased colocalization at the nuclear envelope. Interestingly, fluvoxamine treatment increased Pom121 protein expression without affecting transcription. In C9orf72 -ALS, the nuclear translocation of TFEB autophagy factor decreased owing to nucleocytoplasmic transport defects. Our results showed that pretreatment of NSC34 cells with fluvoxamine promoted the shuttling of TFEB into the nucleus and elevated the expression of LC3-II compared to the overexpression of (G 4 C 2 ) 31 -RNA alone. Additionally, even when used alone, fluvoxamine increases Pom121 expression and TFEB translocation. To summarize, fluvoxamine may act as a promising repurposed medicine for patients with C9orf72 -ALS, as it stabilizes the nucleoporin Pom121 and promotes the translocation of TFEB in (G 4 C 2 ) 31 -RNA-expressing NSC34 cells.

neurosciences

What problem does this paper attempt to address?

### What problems does this paper attempt to solve?

This paper aims to explore the potential therapeutic role of Fluvoxamine in C9orf72 - related amyotrophic lateral sclerosis (ALS). Specifically, the research attempts to address the following issues:

1. **Pathological mechanisms of ALS and FTD**: G4C2 RNA repeat expansion (hexanucleotide repeat expansion, HRE) is one of the causes of ALS and frontotemporal dementia (FTD). This expansion can lead to nuclear - cytoplasmic transport defects, which in turn affect the nuclear transport of key proteins such as TFEB (transcription factor EB), and ultimately lead to autophagy dysfunction.

2. **The role of Sigma - 1 receptor**: Sigma - 1 receptor (Sigma - 1 receptor, Sig - 1R) is a protein that can provide neuroprotective effects, especially in ALS and Alzheimer's disease. However, its activation mechanism and its impact on (G4C2)n - RNA - induced cell death are still unclear.

3. **Mechanism of action of Fluvoxamine**: As a Sig - 1R agonist, can Fluvoxamine promote the nuclear transport of TFEB and restore autophagy function by stabilizing the expression of Pom121 protein in the nuclear pore complex, thereby alleviating the symptoms of ALS?

### Main findings of the study

1. **Fluvoxamine as a Sig - 1R agonist**: The study shows that Fluvoxamine can enhance the chaperone activity of Sig - 1R and reduce the binding of BiP to Sig - 1R, thereby activating Sig - 1R.

2. **Stabilizing Pom121 protein expression**: Fluvoxamine can stabilize Pom121 protein expression without affecting its mRNA level. This indicates that Fluvoxamine increases the stability of Pom121 by inhibiting protein degradation.

3. **Promoting TFEB nuclear transport**: Fluvoxamine treatment promotes the transport of TFEB from the cytoplasm to the nucleus and increases the expression of LC3 - II, indicating that autophagy function is improved.

4. **Potential therapeutic applications**: Based on the above findings, Fluvoxamine may be a promising drug for the treatment of C9orf72 - ALS patients because it can stabilize the nucleoporin Pom121 and promote the nuclear transport of TFEB.

### Conclusion

This study reveals the mechanism by which Fluvoxamine improves autophagy function by activating Sig - 1R, stabilizing Pom121 protein expression, and promoting TFEB nuclear transport. These findings provide important scientific basis for the development of new therapies for C9orf72 - ALS.